

Amendments to the Claims

Please amend the claims as follows:

1. (Original) Method for the treatment of schizophrenia with an antipsychotic agent administered to a patient with overweight wherein that the antipsychotic agent is asenapine.
2. (Original) Method for the treatment with asenapine of schizophrenia in a patient that was having weight gain due to another antipsychotic agent.
3. (Original) Method for the treatment with asenapine of schizophrenia in a patient that needs to be protected against weight increase due to the presence of risk factors for a disease for which overweight is also a risk factor or due to the presence of other weight increasing factors.
4. (Original) The method according to claim 1 wherein the overweight is defined to be a BMI of ≥ 25 .
5. (Original) The method according to claim 4 wherein the overweight is defined to be a BMI of ≥ 27.8 for men and ≥ 27.3 for women.
6. (Currently amended) The method according to ~~any one of~~ claims 1 —5 wherein asenapine is administered to the patient by the sublingual route.
7. (Original) Use of an antipsychotic agent in the manufacture of a medicament for the treatment of schizophrenia in a patient with overweight wherein the antipsychotic agent is asenapine.
8. (Original) Use of asenapine in the manufacture of a medicament for the treatment of schizophrenia administered to a patient wherein the patient was having weight gain due to another antipsychotic agent.
9. (Original) Use of asenapine in the manufacture of a medicament for the treatment of schizophrenia administered to a patient wherein the patient needs to

be protected against weight increase due to the presence of risk factors for a disease for which overweight is also a risk factor or due to the presence of other weight increasing factors.

10. (Original) The use of claim 7 wherein the overweight is defined to be a BMI of ≥ 25 .

11. (Original) The use of claim 9 wherein the overweight is defined to be a BMI of ≥ 27.8 for men and ≥ 27.3 for women.

12. (Currently amended) The use of claims 7-11 wherein the medicament is to be administered to the patient by the sublingual route.

13. (New) The method according to claim 2 wherein asenapine is administered to the patient by the sublingual route.

14.(New) The method according to claim 3 wherein asenapine is administered to the patient by the sublingual route.

15.(New) The method according to claim 4 wherein asenapine is administered to the patient by the sublingual route.

16. (New) The method according to claim 5 wherein asenapine is administered to the patient by the sublingual route.

17. (New) The use of claim 8 wherein the medicament is to be administered to the patient by the sublingual route.

18. (New) The use of claim 9 wherein the medicament is to be administered to the patient by the sublingual route.

19.(New) The use of claim 10 wherein the medicament is to be administered to the patient by the sublingual route.

20. (New) The use of claim 11 wherein the medicament is to be administered to the patient by the sublingual route.